REDWOOD CITY, Calif. — Biotricity, a medical diagnostic and consumer health care technology company, has expanded its sales team and scientific advisory board to focus on tailoring its flagship product, Bioflux, for preemptive heart disease identification in new markets. “The focus of health care is shifting toward outpatient health care, with prevention at the forefront of this movement,” said Casey Shattuck, vice president of sales at Biotricity, in a statement. “Our Bioflux has proven to be a formidable technology as we continue to gain significant clinical approval and adoption in emerging markets of outpatient monitoring. We truly believe we are entering the infancy of outpatient monitoring.” Biotricity has already identified three potential markets where its technology can be applied and plans to announce more details on this initiative over the next three quarters. Shattuck said the company considers remote monitoring medical-grade devices a significant component of its product development roadmap and plans to expand its offering with time.
You are here: / / Biotricity expands sales team, scientific advisory board